ligelizumab + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Allergy, Peanut
Conditions
Allergy, Peanut
Trial Timeline
Dec 7, 2021 → Nov 27, 2023
NCT ID
NCT04984876About ligelizumab + Placebo
ligelizumab + Placebo is a phase 3 stage product being developed by Novartis for Allergy, Peanut. The current trial status is terminated. This product is registered under clinical trial identifier NCT04984876. Target conditions include Allergy, Peanut.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04984876 | Phase 3 | Terminated |
| NCT04513548 | Phase 1 | Terminated |
| NCT03437278 | Phase 2 | Completed |
Competing Products
20 competing products in Allergy, Peanut